These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25937244)

  • 21. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis.
    Fragiadaki K; Tektonidou MG; Konsta M; Chrousos GP; Sfikakis PP
    J Rheumatol; 2012 Jan; 39(1):60-2. PubMed ID: 22133618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
    Kremer JM; Blanco R; Halland AM; Brzosko M; Burgos-Vargas R; Mela CM; Rowell L; Fleischmann RM
    Clin Exp Rheumatol; 2016; 34(4):625-33. PubMed ID: 27087059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project.
    Backhaus M; Ohrndorf S; Kellner H; Strunk J; Backhaus TM; Hartung W; Sattler H; Albrecht K; Kaufmann J; Becker K; Sörensen H; Meier L; Burmester GR; Schmidt WA
    Arthritis Rheum; 2009 Sep; 61(9):1194-201. PubMed ID: 19714611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.
    Sweet K; Dasgupta B; de Vries D; Gourley I; Hsu B; Loza MJ; Taylor PC
    Ann Rheum Dis; 2019 Oct; 78(10):1439-1441. PubMed ID: 31018960
    [No Abstract]   [Full Text] [Related]  

  • 25. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate.
    Mease P; Strand V; Shalamberidze L; Dimic A; Raskina T; Xu LA; Liu Y; Smith J
    Ann Rheum Dis; 2012 Jul; 71(7):1183-9. PubMed ID: 22328739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
    Aletaha D; Smolen JS
    Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents.
    Pincus T; Richardson B; Strand V; Bergman MJ
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-47-54. PubMed ID: 25365089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rheumatoid arthritis: time for trials of therapeutic targets.
    Edmonds J; Lassere M
    J Rheumatol; 2002 Oct; 29(10):2041-4. PubMed ID: 12375309
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of clinical scores to guide therapeutic decisions in patients with rheumatoid arthritis in daily care.
    Malysheva O; Bedrich A; Kuipers JG; Kleine H; Wolff B; Baerwald CG
    Clin Exp Rheumatol; 2015; 33(2):255-8. PubMed ID: 25896474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
    Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
    Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot study assessing the novel use of musculoskeletal ultrasound in patients with rheumatoid arthritis to improve patient attitudes and adherence to medication.
    Joplin SK; van der Zwan R; Bagga H; Joshua F; Wong PK
    Int J Rheum Dis; 2016 Jul; 19(7):658-64. PubMed ID: 24839920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection.
    Giannitti C; Fineschi I; Frediani B; Fioravanti A; Galeazzi M
    Clin Exp Rheumatol; 2013; 31(5):816. PubMed ID: 24021246
    [No Abstract]   [Full Text] [Related]  

  • 33. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.
    Kameda H; Sekiguchi N; Nagasawa H; Amano K; Takei H; Suzuki K; Nishi E; Ogawa H; Takeuchi T
    Mod Rheumatol; 2006; 16(6):381-8. PubMed ID: 17165001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial.
    Keystone EC; Combe B; Smolen J; Strand V; Goel N; van Vollenhoven R; Mease P; Landewé R; Fleischmann R; Luijtens K; van der Heijde D
    Rheumatology (Oxford); 2012 Sep; 51(9):1628-38. PubMed ID: 22596211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient.
    Pers YM; Godfrin-Valnet M; Lambert J; Fortunet C; Constant E; Mura T; Pallot-Prades B; Jorgensen C; Maillefert JF; Marotte H; Wendling D; Gaudin P
    J Rheumatol; 2015 Apr; 42(4):580-4. PubMed ID: 25641885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
    Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
    [No Abstract]   [Full Text] [Related]  

  • 40. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study).
    Mori S; Yoshitama T; Hidaka T; Hirakata N; Ueki Y
    Ann Rheum Dis; 2015 Mar; 74(3):627-30. PubMed ID: 25561361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.